Loading...
XASXPER
Market cap31mUSD
Jan 29, Last price  
0.06AUD
Name

Antisense Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:PER chart
P/E
P/S
31.96
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
26.65%
Rev. gr., 5y
-55.61%
Revenues
2m
-11.14%
000762,3686,399,0000000003,863,9881,000,00069,1150586,788668,433577,7641,777,9041,579,849
Net income
-11m
L+95.06%
-4,609,624-6,265,839-5,462,401-4,835,963-2,136,886-2,649,727-3,424,875-1,813,550-1,801,278-2,454,842-3,013,272706,918-2,514,443-2,754,799-2,331,015-2,305,862-5,890,210-8,067,192-5,834,080-11,379,828
CFO
-8m
L+4.44%
-2,209,608-5,585,305-3,958,499-2,679,528-3,401,498-3,283,821-1,336,627-1,867,239-2,405,200-2,833,186-3,107,8861,268,875-2,025,026-2,914,2220-2,928,436-3,945,358-5,834,156-7,805,166-8,151,329
Earnings
Feb 26, 2025

Profile

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
IPO date
Dec 20, 2001
Employees
8
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,580
-11.14%
1,778
207.72%
Cost of revenue
14,573
8,664
Unusual Expense (Income)
NOPBT
(12,993)
(6,887)
NOPBT Margin
Operating Taxes
(377)
22
Tax Rate
NOPAT
(12,616)
(6,909)
Net income
(11,380)
95.06%
(5,834)
-27.68%
Dividends
(79)
Dividend yield
0.17%
Proceeds from repurchase of equity
21,101
BB yield
-44.36%
Debt
Debt current
94
94
Long-term debt
190
361
Deferred revenue
Other long-term liabilities
7
1
Net debt
(10,683)
(18,778)
Cash flow
Cash from operating activities
(8,151)
(7,805)
CAPEX
(29)
(4)
Cash from investing activities
(29)
(4)
Cash from financing activities
(85)
21,022
FCF
(11,650)
(7,830)
Balance
Cash
10,967
19,233
Long term investments
Excess cash
10,888
19,144
Stockholders' equity
9,976
21,141
Invested Capital
149
2,226
ROIC
ROCE
EV
Common stock shares outstanding
634,294
634,294
Price
0.06
-21.33%
0.08
-61.54%
Market cap
37,423
-21.33%
47,572
-54.90%
EV
26,740
28,794
EBITDA
(12,898)
(6,797)
EV/EBITDA
Interest
22
Interest/NOPBT